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The influence of long-term verapamil administration on the 
consequences of Trypanosoma cruzj infection in mice was 
studied with regard to animal mortality, morbidity, myo- 
cardial pathologic features and myocardial beta-adrenergic 
adenylate cyclase activity. Verapamil administration dra- 
matically decreased the mortality rate from 60% to 6% 
during the 70 day period of h&&ion. Three clinical stages 
of infection were evident. In the acute stage (17 days after 
Infection with maximal parasitemia), verapamil treatment 
not only decreased the incidence of myocardial disease 
(fibrosis and inflammation), but also protected myocardial 
beta-adrenergic adenylate cyclase activity. In addition, 
there was no increase in total body weight, which was 
regarded as an index of right-sided heart failure. In the 
subacute stage (30 to 60 days after infection), administra- 
tion of verapamil continued to decrease myocardial disease 
The hypothesis that abnormalities in calcium metabolism 
play a crucial role in the pathogenesis of cardiomyopathy has 
received substantial attention in the past decade (1-4). In the 
Syrian hamster with congenital cardiomyopathy, increased 
levels of calcium uptake have been observed in the myocar- 
dium at a time when characteristic pathologic lesions first 
appear (5). Prolongation of the action potential duration has 
also been demonstrated in these hamsters, and could be 
explained by an enhanced slow inward calcium current (6). 
The most impressive evidence in support of a critical role for 
calcium in the pathogenesis of cardiomyopathy comes from 
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and preserve beta-adrenergic adenylate cyclase activity. In 
addition, verapamil ameliorated the morbidity and mortal- 
ity associated with this stage of infection. 
The chronic stage of InfectIon was characterized by a 
decrease in myocardial disease and in beta-adrenergic 
adenylate cyclase activity. Thus, independent of the state of 
infection, long-term verapamil treatment enhanced beta- 
adrenergic adenylate cyclase activity. In addition, vera- 
parnil ameliorated the morbidity associated with infection. 
Although the relation among these various effects of vera- 
pamil in the setting of T. cnrzi infection remains to be 
determined, collectively the results suggested that vera- 
pamil administration attenuated the consequences of T. 
cruzi infection. 
(J Am Coil Cardiol1989;14:782-9) 
observations made with verapamil, a calcium channel block- 
ing agent (7-9). Long-term administration of verapamil not 
only prolonged the survival of hamsters with cardiomyopa- 
thy, but also prevented the occurrence of the pathologic 
lesions (7-9). 
Over the past several years, we studied another model of 
cardiomyopathy, that of murine chagasic cardiomyopathy in 
a mouse infected with the hemoflagellate Trypano~~llza cruzi 
(10). In this experimental cardiomyopathy, many myocardial 
pathologic features are shared in common with those seen in 
the Syrian hamster, including focal fibrosis and inflammation 
(I 1,12). As with the Syrian hamster, microvascular involve- 
ment is also a prominent feature of murine chagasic cardio- 
myopathy (11). Recently, we documented (10) that infection 
with T. cruzi profoundly diminished beta-adrenergic adenyl- 
ate cyclase activity, as also observed in the Syrian hamster 
and in other cardiomyopathic states (13-17). Collectively, 
these observations suggested that the murine model of 
chagasic cardiomyopathy and the Syrian hamster with car- 
diomyopathy may share common pathophysiologic mecha- 
nisms. Therefore, we explored the possibility that verapamil 
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influenced murine chagasic cardiomyopathy in a manner 
similar to that observed in the Syrian hamster. Using mice 
infected with T. cruzi, we determined the influence of 
long-term verapamil administration on mortality, morbidity, 
myocardial disease and the beta-adrenergic adenylate cy- 
clasc complex. 
Methods 
Experimental design. Six to 8 week old male CD-1 mice 
(15 to 20 g) were obtained from Charles River Breeding 
Laboratories (Wilmington, Massachusetts). Mice were clas- 
sified into four groups: uninfected not given verapamil (C), 
uninfected given verapamil (V), infected not given verapamil 
(TC) and infected given verapamil (TV). In light of the 
expected mortality rate for infected animals. in experiment 1, 
there were 50 mice in each TC and TV group, and 25 in each 
C and V group (total 150 animals). In experiment II, there 
were 60 mice in each group, except TC, which had 90 mice 
(total 270). In experiment I, 60% of all mice in each group 
were randomly chosen for analysis of disease, whereas in 
experiment 11, 30% of mice in each group were randomly 
chosen for analysis of disease. For quantification of the 
influence of verapamil on infection-associated mortality, two 
additional experiments with a total of 100 animals were 
performed. Infection was established with T. cruzi (Brazil 
strain) by intraperitoneal injection of lo4 trypomastigotes on 
day 0. Parasitemia was followed in each group by counting 
the organisms with a Neubauer hemocytometer, as previ- 
ously described (IO). Parasitemia usually peaked at approx- 
imately day 17 and was not significantly affected by treat- 
ment with verapamil (data not shown). Mice were killed for 
pathologic and biochemical studies at the time points dis- 
cussed in the Results section. Mice were observed for 
clinical illness on a daily basis. Water consumption and 
weight were measured every 4 days. 
Parasites. The Brazil strain of 7. cruzi was passaged in 
C3H mice (Jackson Laboratories, Bar Harbor, Maine). as 
previously described (10). 
Administration of verapamil. Verapamil was adminis- 
tered in the only water supply at a concentration of I g/liter. 
On the basis of an observed daily consumption of 3.5 ml of 
water, it was calculated that these mice consumed 3.5 mg of 
drug daily, or approximately 100 mgikg daily. As determined 
from pharmacokinetic data, the mean steady state serum 
concentration in the treated mice was approximately 1 
&ml. In vitro studies showed that verapamil had no effect 
on the infectivity of parasites at the concentration employed 
in this study. 
Preparation of myocardial membranes and tissue. The 
heart was rapidly excised from mice anesthetized with ether, 
and immediately placed in ice-cold 0.15 M saline solution. 
Within 30 min, the heart was freed of large vessels, atria, fat 
and blood and minced in buffer (0.25 M sucrose, 0.03 M 
histidine, pH 7.4 with 5 mM ethylenediamine tetraacetic acid 
[EDTA]). The ventricular tissue was homogenized with a 
polytron (Brinkman Corporation) at 4°C. The resulting crude 
homogenate was centrifuged at 11,000 x g for 20 min at 4°C. 
Supernatant was immediately centrifuged at 43,000 x g for 
30 min at 4°C. This final pellet was resuspended in the 
homogenizing buffer without EDTA and stored at -60°C. 
Membranes retained adenylate cyclase activity without 
change for up to 3 months. This preparation was used 
directly in the adenylate cyclase assay. 
Pathology. The mouse heart was excised as just de- 
scribed and immediately fixed in 10% neutral buffered for- 
malin. The heart was bisected in the apex to base plane 
perpendicular to the ventricular septum to facilitate exami- 
nation of atria, ventricles and conduction tissue. Both halves 
of the heart were embedded in paraffin and sectioned at 5 
FM. Three levels were prepared from each heart and were 
stained with hematoxylin-eosin and Masson’s trichrome. 
Individual slides were prepared and scored for the extent of 
myocardial inflammation and fibrosis as well as the presence 
of pseudocysts. The physical condition of the animal from 
which the slides were obtained was unknown to the exam- 
iner. 
Scoring was perjormed jbr the atrium, right and left 
ventricle and base in the following manner: where no 
inflammation or fibrosis was observed, the score of 0 was 
applied; in the event of minimal inflammation or fibrosis, a 
score of 1 was applied; in like manner, a score of 2, 3 and 4 
was given to a slide showing mild, moderate and extensive 
inflammation and fibrosis, respectively. For each heart ex- 
amined, composite scores for inflammation and fibrosis were 
then derived. Although four distinct areas of the heart were 
examined. regional differences were not statistically signifi- 
cant; therefore. all values for a given heart were pooled. The 
maximal score for inflammation or fibrosis was 16. These 
scores were ranked, and statistical significance among 
groups was determined with use of nonparametric Wilcoxon 
analysis. Mean scores for each group were calculated as 
well. 
Adenylate cyclase assay. The reaction mixture contained 
50 mM TRIS hydrochloride (HCI) (pH 7.4), 2.5 mM magne- 
sium unless otherwise noted, 0.143 mM adenosine triphos- 
phate (ATP), an ATP-regenerating system (creatine phos- 
phate/creatine kinase). ATP ([cx-~~P]ATP. 1 to 2 x lo6 
cpmlassay tube) and 6 mM theophylline in a final volume of 
75 ~1 (17). Agents dissolved in 50 mM TRIS HCI (pH 7.5) 
were added in concentrations noted in individual experi- 
ments. The adenylate cyclase reaction was terminated by the 
addition of an ATP-cyclic adenosine monophosphate (AMP) 
“stopping solution” (18). Isolation of [32P]cyclic AMP was 
accomplished by sequential Dowex and alumina chromatog- 
raphy with use of [‘HIcyclic AMP as a recovery marker (19). 
The maximal isoproterenol activity (Vmax) for isoproter- 
enol was determined from an analysis of the dose-response 
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Table 1. Mortality Data for T. cruti-Infected Mice 
Group Died Alive 
TV 3 45 
TC 19* 29 
*p < 0.01 compared with T. cruzi-infected mice treated with verapamil. 
The TV (T. cruzi-infected mice treated with verapamil) and TC (T. cruzC 
infected mice not treated) were maintained under conditions noted in the 
Methods section. “Died” indicates the number of mice that died during a 70 
day period of observation. There were no deaths observed in verapamil- 
treated or untreated animals that were not infected with T. crrrii. 
relation for isoproterenol-dependent activation of adenylate 
cyclase activity in myocardial membranes, as previously 
described (10). Each Vmax represents the contribution of 
the mean values of 12 triplicate measurements of adenylate 
cyclase activity. The Kact is the concentration of isoproter- 
enol associated with 50% maximal adenylate cyclase activity 
(Vmax) determined under these reaction conditions. 
Materials. [32P]ATP and [3H]cAMP were obtained from 
New England Nuclear-E. I. du Pont de Nemours and Com- 
pany, Inc. Gpp(NH)p was obtained from Sigma Corpora- 
tion. Pertussis toxin was obtained from List Laboratories 
and cholera toxin from Schwartz Mann Laboratories. All 
other reagents were of the highest purity commercially 
available. 
Analysis of data. Determinations of apparent Kact and 
Vmax for adenylate cyclase activation by agents were made 
using linear regression analysis of the double reciprocal 
(Lineweaver Burke analysis) of l/(V-Vo) versus l/S, where 
Vo was adenylate cyclase activity in the absence of the agent 
under consideration, and V was the adenylate cyclase activ- 
ity in the presence of the agent at concentration S. Signifi- 
cance was determined using Student’s f test. 
Results 
Mortality from T. cruzi infection and the influence of 
infection (Table 1). The mortality rate was significantly 
reduced when T. cruzi-infected mice were treated with 
verapamil. Fewer than 40% of infected untreated mice (TC) 
survived at the end of 70 days. In marked contrast, >80% of 
infected mice treated with verapamil (TV) survived the same 
interval. By life table analysis, the cumulative probability of 
being alive in group TC at day 70 was 0.21 f 0.16 and in 
group TV was 0.76 * 0.23. The majority (90%) of deaths 
occurred between 28 and 40 days after infection. 
Myoeardiai disease from infection and the influence of 
verapamil (Table 2). Having established the influence of 
verapamil on the overall mortality rate from T. cruzi infec- 
tion in mice, we next examined the influence of the calcium 
channel blocker on myocardial disease (that is, inflammation 
and fibrosis) during selected time periods of infection. In 
general, the mean scores for inflammation and fibrosis at all 
Table 2. Mean Pathology Scores for Inflammation and Fibrosis 
Inflammation Fibrosis 
Day TV (n) TC (n) TV (n) TC (n) 
Experiment 1 
33 12.7 (3) 13.7 (8) 
45 5.5 (6) 9.4 (6) 
6O 2.8 (7)* 4.6 (5) 
90 0.3 (7)* 3.0 (4) 
119 1.0 (II)* 2.3 (4) 
Experiment II 
17 6.6 (7) 7.8 (7) 
31 9.2 (7)* 11.7 (6) 
64 I .2 (5)3 3.7 (8) 
9.8 (3) 11.4 (8) 
5.6 (6)* 10.8 (6) 
1.8 (7)* 5.4 (5) 
0.3 (7)* 3.8 (4) 
0.9 (II) I.5 (4) 
2.6 (7) 4.2 (7) 
4.5 (7)* 9.7 (6) 
1.4 (5)* 4.4 (8) 
*p < 0.05 Wilcoxon analysis, one-tailed test. All scores are average 
pathology scores seen in the right and left ventricle, atrium and base of the 
heart. Each area of the hear? was scored from 0 (no disease) to 4 (severe 
inflammation or fibrosis). The maximal score for inflammation or fibrosis on a 
particular heart was 16. Standard deviations for individual measurements are 
~15% of the mean values, and for purposes of clarity are omitted here. (n) = 
number of mice at each time point; other abbreviations as in Table 1. 
time points examined were less in infected mice treated with 
verapamil than in untreated mice. Specifically, there was a 
consistent decrease in disease, which was significant (p < 
0.05) at multiple time points by nonparametric analysis, and 
the overall trend was significant (p < 0.05) by the Sign test. 
It should be noted that maximal fibrosis and inflammation 
were observed by 33 days for infected animals in both 
experiments, independent of treatment with verapamil. By 
60 days, the extent of fibrosis and inflammation dramatically 
diminished from 12.7 to 4.6 and from 11.7 to 3.7 in experi- 
ments 1 and II, respectively. No disease was seen in unin- 
fected animals regardless of treatment (data not shown). 
Verapamil treatment had no effect on the presence of 
pseudocysts, which were numerous in both treatment groups 
(TV and TC) on day 17, but absent by day 45. 
Clinical consequences of infection and the influence of 
verapamil. The magnitude of myocardial disease varied with 
the duration of infection. Likewise, the clinical course of 
infected mice also varied with the duration of infection. This 
latter pattern conformed to three clinical stages of infection 
similar to the course of infection in humans. In the acute 
stage of infection (17 days after infection), body weight had 
increased by 15% (Fig. 1). In this acute stage, infected mice 
were indistinguishable from their uninfected littermates de- 
spite maximal parasitemia (10). Furthermore, verapamil 
treatment of infected mice greatly attenuated the increased 
body weight. 
In the subacute stage that occurred 33 days after infec- 
tion (and for approximately 20 days thereafter), body weight 
increased 25% above that observed in uninfected animals. 
This stage of infection was also characterized by onset of 
obvious morbidity, manifested by increasing abdominal girth 
and decreasing spontaneous activity despite the absence of 
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Figure 1. Alterations in body and lung weight and the duration of 
infection. Total body (open bars) and lung (&WI bars) weights were 
determined for each infected and uninfected mouse at 17,33 and 66 
days (acute, subacute and chronic stages, respectively). The mean 
or control value was determined from measurements made in the 
uninfected and untreated group of the corresponding age. The 
values shown here are the percent change in mean weights com- 
pared with the control value (that is, uninfected untreated mice). 
Treatment of uninfected mice with verapamil (V) did not apprecia- 
bly change either body or lung weight, and these results are omitted 
from this figure. The n values for each group were identical to those 
shown in Table 2. Shown here are the results obtained from 
experiment II, which were qualitatively indistinguishable from those 
obtained in experiment I. All changes >lO% are statistically signif- 
icant (p < 0.01) from uninfected untreated mice. 
parasitemia. Morbid mice included only 5% to 15% of 
infected mice; the majority of these died within 3 to 7 days 
after the onset of symptoms, accounting for >!90% of the 
total mortality rate observed in infected mice. It is interest- 
ing to note that during this stage, maximal myocardial 
inflammation and fibrosis were found (Table 2). In suba- 
cutely infected mice treated with verapamil, there was only 
a 2.5% increase in body weight. 
In the stage of chronic infection (66 days after infection), 
there was no significant difference in body weight among all 
groups of mice. In addition, chronically infected mice were 
clinically indistinguishable from uninfected control mice. 
Myocardial beta-adrenergic adenylate cyclase activity dur- 
ing infection and the influence of verapamil. We next deter- 
mined infection-associated changes in the activity of the 
myocardial beta-adrenergic adenylate cyclase complex and 
the associated influence of verapamil as a function of the 
stage of infection. Myocardial beta-adrenergic adenylate 
cyclase activity has long been known to play a critical role in 
myocardial function, particularly through the interaction of 
cyclic adenosine monophosphate (CAMP) and Ca”. Fur- 
thermore, ventricles obtained from patients with heart fail- 
ure have demonstrated a marked reduction of beta- 
adrenoceptor density, isoproterenol-mediated adenylate 
cyclase stimulation and myocardial contractility (15). At 17. 
33 and 66 days (acute, subacute and chronic, respectively), 
we determined the Vmax and apparent Kact for isoprotere- 
nol-dependent adenylate cyclase activation in the presence 
and absence of Gpp(NH)p in myocardial membranes, as 
previously described (10). The Vmax for isoproterenol de- 
creased by almost 50% in the acute stage of infection and by 
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Figure 2. The influence of infection with T. cruzi on Vmax for 
isoproterenol. Results shown here are from experiment II and are 
essentially indistinguishable from those derived from experiment I. 
Membranes were assayed from uninfected mice (open bar) and 
infected mice (hatched bar). Acute, subacute and chronic refer to 17, 
33 and 66 days of infection, respectively. *Significantly different 
from uninfected mice at p < 0.01, 
30% in the subacute stage of infection (Fig. 2). In contrast, 
little or no change in Vmax for isoproterenol occurred in 
chronically infected mice. 
Treatment of both uninfected and infected mice with 
verapamil dramatically altered the activity of the beta- 
adrenergic adenylate cyclase complex. For uninfected mice, 
verapamil treatment increased the Vmax for isoproterenol 
(Fig. 3). The effect was greater than twofold in mice at 17 
days (acute control mice), whereas at 66 days (chronic 
control mice), the verapamil-associated increase in isopro- 
Figure 3. Influence of verapamil on the Vmax for isoproterenol 
during the course of infection with T. cruzi. The Vmax for isopro- 
terenol was determined in myocardial membranes prepared from 
uninfected untreated animals (C), uninfected and verapamil-treated 
mice (V), infected and untreated mice (TC) and infected and 
verapamil-treated mice (TV). The data for uninfected treated ani- 
mals (V) (open bars) and infected treated animals (hatched bars) 
were then expressed as the percent of Vmax for isoproterenol in 
uninfected untreated animals (taken from Fig. 2). Data shown here 
are from experiment II and are essentially indistinguishable from the 
data derived from experiment I. Horizontal dotted line indicates 
100% value, or isoproterenol-dependent adenylate cyclase activity 
determined in uninfected untreated animals (C). 
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Figure 4. The influence of T. rruzi infection on Vmax for isopro- 
terenol-dependent adenylate cyclase activation measured in the 
presence of Gpp(NH)p. Results, procedures and membranes shown 
here are as described in legend to Figure 3, except that the adenylate 
cyclase assays were carried out in the presence of 1 PM of 
Gpp(NH)p. *Significantly different from uninfected untreated mice 
at p < 0.01. 
terenol-dependent Vmax was 60% above the isoproterenol 
adenylate cyclase activity observed in untreated uninfected 
animals. 
In the acute and subacute stage of infection, verapamil 
treatment also increased isoproterenol-dependent adenylate 
cyclase activity, resulting in levels equal to or slightly higher 
then the isoproterenol-dependent adenylate cyclase activity 
observed in uninfected untreated control animals (Fig. 3). 
Thus, verapamil administration restored the isoproterenol- 
dependent Vmax in infected mice to a level observed in 
age-matched uninfected animals. Verapamil treatment of 
infected mice did not increase isoproterenol-dependent ade- 
nylate cyclase activity to levels observed in verapamil- 
treated but uninfected animals. 
Activation of adenylate cyclase activity by isoproterenol 
involves interactions between the beta-adrenergic receptor, 
the coupling guanine nucleotide binding protein and the 
catalytic unit. In light of our previous evidence (10) impli- 
cating an influence of infection on the guanine (G) nucleotide 
binding protein itself, we evaluated isoproterenol-dependent 
adenylate cyclase activity in the presence of Gpp(NH)p. In 
this setting, the influence of Gpp(NH)p more directly reflects 
the activity of the guanine nucleotide binding protein (20). In 
uninfected mice, Gpp(NH)p markedly increased Vmax for 
isoproterenol-dependent adenylate cyclase activity from 5.9, 
4.9 and 5.54 pmolimg per min (Fig. 3) to 14, 9.8 and 8.4 
pmol/mg per min in mice at 17, 33 and 66 days (control mice 
for acute, subacute and chronic infection, respectively) (Fig. 
4). This constituted a 140%, 100% and 50% Gpp(NH)p- 
associated increase in isoproterenol-dependent adenylate 
cyclase activity, respectively. The synergistic action of 
Gpp(NH)p was also observed in infected mice. Thus, Gpp- 
(NH)p increased the Vmax for isoproterenol-dependent ad- 
enylate cyclase activity from 3.4, 3.2 and 5.2 pmol/mg per 
min (Fig. 2) to 7. I, 6.6 and 8.4 pmolimg per min (Fig. 3) in 
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Figure 5. The influence of verapamil treatment on Vmax for iso- 
proterenol in the presence of Gpp(NH)p during the course of 
T. cruzi infection. Preparation of membranes, analysis of data and 
all other aspects of this figure are as described in the legend to 
Figure 4. 
acute, subacute and chronic infection, respectively. The 
presence of Gpp(NH)p increased isoproterenol-dependent 
adenylate cyclase activity in infected mice to a value essen- 
tially equal to the activity in uninfected mice measured in the 
absence of Gpp(NH)p. Thus, both long-term verapamil 
administration and the addition of Gpp(NH)p restored iso- 
proterenol-dependent adenylate cyclase activity in myocar- 
dial membranes from infected mice to the level observed in 
uninfected mice. However, it should be noted that in acute 
and subacute infection, isoproterenol-dependent adenylate 
cyclase activity measured in the presence of Gpp(NH)p was 
substantially less then that activity determined under other- 
wise identical conditions in uninfected animals (7.4 and 6.4 
pmol/mg per min in infected animals vs I4 and 13 pmol/mg 
per min in uninfected animals, at 17 and 33 days, respec- 
tively). 
Verapamil treatment of both uninfected and infected 
mice also increased Vmax for isoproterenol determined in 
the presence of Gpp(NH)p. In myocardial membranes pre- 
pared from verapamil-treated uninfected mice, the vera- 
pamil-associated increase in isoproterenol-dependent ade- 
nylate cyclase activity measured in the presence of 
Gpp(NH)p was approximately 47%, 32% and 60% in mice at 
17, 33 and 66 days (control mice for acute, subacute and 
chronic infection, respectively) (Fig. 5). Verapamil treat- 
ment of infected animals increased isoproterenol-dependent 
adenylate cyclase activity measured in the presence of 
Gpp(NH)p to a level essentially equal to that measured 
under otherwise identical conditions in uninfected but un- 
treated mice. In experiments not shown, we determined that 
the addition of verapamil directly to the adenylate cyclase 
assay did not significantly influence the activity levels mea- 
sured. 
We next determined if the action of verapamil treatment 
on isoproterenol-dependent adenylate cyclase activity could 
be accounted for by a treatment-associated change in sen- 
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Table 3. T. cruzi Infection and the Influence of Verapamil on the 
Apparent Kact for Isoproterenol-Dependent Adenylate Cyclase 
Activity in Mouse Myocardial Membranes 
Apparent Kact for Isoproterenol (PM) 
Alone +Gpp(NWp (1 PM) 
Untreated 
Uninfected (C) 
Infected (TC) 
Verapamil treated 
Uninfected (V) 
Infected (TV) 
0.610 ? 0.18 0.231 + 0.05 
0.615 2 0.16 0.215 r 0.04 
0.403 -c 0.09 0.141 f 0.06 
0.462 f 0.07 0.221 f 0.07 
&c 
0.100 I.000 10.000 
Preparation of membranes, assay conditions and derivation of Kact for 
isoproterenol were as described in legend to Figure 2. Values shown here 
were derived from analysis of Experiment II. Statistical significance at p < 
0.01 achieved for the influence of verapamil treatment on the Kact for 
isoproterenol-dependent adenylate cyclase activity was measured alone. 
sitivity to catecholanine activation. In myocardial mem- 
branes prepared from acutely, subacutely and chronically 
infected mice, there was no significant infection-associated 
change in the apparent Kact for isoproterenol-dependent 
adenylate cyclase activation from that determined in unin- 
fected mice; hence, all values were analyzed collectively 
(Table 3). Infection also did not alter the Gpp(NH)p- 
associated decrease in the apparent Kact for isoproterenol. 
In contrast, for both uninfected and infected mice, treatment 
with verapamil decreased slightly, though significantly, and 
to the same extent the apparent Kact for isoproterenol (from 
0.6” O.lSand0.62 t 0.14flto0.45 + 0.13and0.48 + 0.14 
fl for uninfected and infected animals, respectively). In 
contrast, verapamil did not appear to influence the Gpp- 
(NH)p-associated decrease in the apparent Kact for isopro- 
terenol-dependent adenylate cyclase activity measured in 
the presence of Gpp(NH)p. 
Association of beta-adrenergic adenylate cyclase activity 
and morbidity. The appearance of obvious morbidity during 
subacute infection (day 33 and for approximately 20 days 
thereafter) permitted us to determine the relation of the 
infection-associated reduction in beta-adrenergic adenylate 
cyclase activity to these clinical signs and symptoms. Ac- 
cordingly, subacutely infected mice were classified into two 
groups: 1) those indistinguishable from their uninfected 
littermates and labeled “well” infected mice, and 2) a 
smaller affected group characterized by increased abdominal 
girth and a decline in spontaneous activity, labeled “sick” 
infected mice (Fig. 6). There was little if any isoproterenol- 
dependent adenylate cyclase activity in the latter group. 
Only in the presence of Gpp(NH)p was isoproterenol- 
dependent adenylate cyclase activity demonstrable (1.8 
pmol/mg per min). In contrast, isoproterenol-dependent ad- 
enylate cyclase activity was demonstrable in infected well 
mice in the absence of Gpp(NH)p activity and was substan- 
tially increased when determined in its presence (from 2.8 to 
6.5 pmol cAMP/mg per min). 
[IsoProterenal] pM 
Figure 6. Isoproterenol-dependent adenylate cyclase activity in the 
presence and absence of Gpp(NH)p: association with sick and well 
subacutely sick mice. In experiment II, subacutely sick mice were 
divided into well (80% of total; open symbols) and sick (20% of total; 
closed symbols) mice on the basis of the appearance of increased 
abdominal girth and decreased spontaneous activity in the latter 
group. Myocardial membrane adenylate cyclase activity was mea- 
sured in response to increasing concentrations of isoproterenol 
determined in the presence (triangles) and absence (circles) of 1 FM 
of GPPPWP. 
Discussion 
Experimental chagasic cardiomyopathy in CD-l mice 
shares many of the pathologic and biochemical characteris- 
tics observed in other models of experimental cardiomyop- 
athy (7-9). In the present report, we have shown that 
long-term verapamil administration 1) significantly attenu- 
ates infection-associated mortality, 2) diminishes myocardial 
inflammation and fibrosis, and 3) reverses the infection- 
associated decrease in isoproterenol-dependent adenylate 
cyclase activity as well as the synergistic contribution of 
Gpp(NH)p to that activity. 
Verapamil and infection-associated mortality. The effect 
of verapamil in reducing mortality from Chagas’ disease is 
similar to that reported in hamsters with cardiomyopathy 
(7-9). The basis for this influence of verapamil on mortality 
is not understood, particularly because we do not have data 
to establish the cause of death in infected mice. In this 
regard, it is tempting to associate the protective influence of 
verapamil on myocardial disease and beta-adrenergic ade- 
nylate cyclase activity (and subsequently survival), but the 
data suggest a more complex relation. In acutely infected 
animals, administration of verapamil appears to be associ- 
ated with less myocardial disease and an increase in beta- 
adrenergic adenylate cyclase activity and normal body 
weight at a time when both uninfected and infected animals 
appeared clinically indistinguishable from each other. In 
contrast, in the subacute stage of infection, verapamil treat- 
ment clearly reduces both the infection-associated abnor- 
malities in myocardial disease and the beta-adrenergic ade- 
nylate cyclase complex as well as morbidity and mortality. 
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Thus, other as yet unidentified consequences of infection 
that contribute to the mortality rate were influenced by 
verapamil. In this regard, it is important to note that despite 
the influence of verapamil on the infection-associated 
changes in beta-adrenergic adenylate cyclase activity and 
myocardial disease, treatment with the calcium channel 
blocker did not noticeably alter the number of pseudocysts. 
Hence, the possibility that verapamil treatment may alter 
parasite penetration or metabolism must also be considered. 
Experimental design. When considering the influence of 
verapamil on infection-associated changes in myocardial 
disease and beta-adrenergic adenylate cyclase activity, at- 
tention must be given to the design of the experiment. The 
data for beta-adrenergic adenylate cyclase activity and myo- 
cardial disease represent the average of pooled values. This 
is particularly relevant in the subacute stage of infection, 
where dividing the animals into well and sick groups dem- 
onstrated that the infection-associated decrease in beta- 
adrenergic adenylate cyclase activity was substantially 
greater in clinically ill animals. In this regard, the inability to 
make a similar distinction regarding myocardial disease 
probably relates to the limitations of the quantitative meth- 
ods employed in this study. Collectively, the data suggest 
that the average changes in adenylate cyclase activity or 
myocardial disease at each stage probably reflect a range of 
altered activities, and with more sensitive physiological 
indexes, it may be possible to correlate the influence of 
infection on beta-adrenergic adenylate cyclase activity with 
the physiologic consequences. Despite these limitations, the 
data provide insights into the influence of verapamil in 
chagasic cardiomyopathy. 
Infection and beta-adrenergic adenylate cyclase activity. 
This report complements our recent study (10) documenting 
the depression of myocardial beta-adrenergic adenylate cy- 
clase activity during infection with Z’. cruzi. The observation 
that in chagasic cardiomyopathy, depression in beta- 
adrenergic adenylate cyclase activity occurs both in the 
presence and in the absence of parasitemia suggests that this 
effect of infection reflects an interaction of factors initiated 
by, but not necessarily dependent on, the actual presence of 
the parasite. In cardiomyopathic states of noninfectious 
origin, depression of beta-adrenergic adenylate cyclase ac- 
tivity has been associated with a decrease in the activity of 
the guanine nucleotide binding protein (21), and the loss of 
synergistic activation by Gpp(NH)p of isoproterenol- 
dependent adenylate cyclase activity during infection is 
compatible with this hypothesis. Whether the depression of 
beta-adrenergic adenylate cyclase activity initiates the car- 
diomyopathic state or follows as a consequence of more 
primary events remains to be determined. 
Biochemical basis for the influence of verapamil. Possible 
mechanisms that may explain the role of verapamil in 
preserving beta-adrenergic adenylate cyclase activity stem 
from previously documented actions of the calcium channel 
blocker. Thus, verapamil maintains vascular perfusion, re- 
lated both to its direct vasodilatory action on smooth muscle 
cells and inhibition of platelet aggregation (9,22,23). Exper- 
imental evidence (24) suggests that a compromise in vascular 
perfusion may lead to a decrease in myocardial beta- 
adrenergic adenylate cyclase activity. Pertinent to the 
present study, depression of adenylate cyclase activity dur- 
ing severe ischemia was avoided by pretreatment with 
verapamil in experimental rats (24). Hence, the documenta- 
tion of microvascular involvement in chagasic and other 
cardiomyopathic states suggests a possible role for vera- 
pamil in blunting or reversing microvascular disease (12,25). 
In this formulation, by virtue of its maintenance of coronary 
perfusion, verapamil maintains adequate beta-adrenergic 
adenylate cyclase activity. This hypothesis finds support in 
other reports on the influence of verapamil in cardiomyopa- 
thy. Thus, long-term administration of verapamil in Syrian 
hamsters with cardiomyopathy was shown (7-9) to preserve 
myocardial contractility, decrease myocytolytic activity, 
abolish microvascular hyperreactivity and diminish the inci- 
dence of fibrosis and calcification. In other experimental 
designs (9), the incidence of fibrosis and inflammation was 
directly correlated with vascular perfusion. Hence, the abil- 
ity of verapamil to maintain vascular perfusion may result in 
a decreased incidence of myocardial disease. In addition to 
its actions in maintaining microvascular perfusion and, thus, 
delaying the expression of myocardial disease, verapamil 
treatment has also been shown to reduce aspects of reper- 
fusion injury, including the generation of peroxide radicals 
(7,26). In our experience (121, we failed to detect the 
extensive microvascular thrombosis and platelet aggregation 
observed by others (25) during the course of I’. cruzi 
infection. However, verapamil may influence microvascular 
spasm that may contribute to the infection-associated patho- 
logic and biochemical changes. 
The influence of verapamil on vascular perfusion does not 
adequately explain the action of the calcium channel blocker 
in uninfected mice in which long-term administration of the 
agent also resulted in an increase in beta-adrenergic adenyl- 
ate cyclase activity. In normal human control subjects, 
verapamil administration has been reported (26) also to 
increase isoproterenol-dependent adenylate cyclase activity 
in peripheral lymphocytes without a change in receptor 
density, but with an increase in agonist binding tinity. 
Serum norepinephrine also decreased with verapamil admin- 
istration, suggesting that the verapamil-associated increase 
in isoproterenol-dependent adenylate cyclase activity re- 
flects denervation supersensitivity. In this regard, we failed 
to observe an influence of infection on myocardial catechol- 
amines (results not shown) in mice. However, in preliminary 
experiments (results not shown), we observed that growth of 
L6E9 myoblasts after the administration of verapamil was 
associated with an increase in beta-adrenergic adenylate 
cyclase activity, suggesting that the influence of the drug 
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may be more direct and not necessarily related to a reduction 
in the level of circulating catecholamines. Thus, the protec- 
tive effect of verapamil on beta-adrenergic adenylate cyclase 
activity during T. cruzi infection and the enhancement of 
beta-adrenergic adenylate cyclase activity by verapamil in 
uninfected animals may be a consequence of both the direct 
or indirect effects of the calcium channel blocker, but with 
quantitatively different contributions. 
Verapamil and chronic infection. In the chronic stage of 
infection, infected and uninfected mice are clinically indis- 
tinguishable. With the possible exception of a small decrease 
in the incidence of myocardial disease, the influence of 
verapamil on the beta-adrenergic adenylate cyclase activity, 
morbidity and mortality is identical in both uninfected and 
infected mice. In this regard, the decreased incidence of 
fibrosis and inflammation in chronic infection probably re- 
flects the survival bias of the experiment (that is? the 
incidence of myocardial disease does not decline after 66 
days, but rather the more affected mice having more severe 
myocardial disease have already died). Similar consider- 
ations may apply to the influence of infection on the beta- 
adrenergic adenylate cyclase complex. It remains to be 
determined whether the chronically infected mice ultimately 
succumb to disease and, more importantly, whether vera- 
pamil similarly influences the expression of this aspect of 
Chagas’ disease. Experiments to determine this are cur- 
rently in progress, 
We gratefully acknowledge the technical assistance of Vicki Braunstein and 
Gloria Baron. 
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